Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02144181 · ClinicalTrials.gov registry record · NA
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
A NA study, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT02144181 is a NA study that has completed, run by Ulthera. The registered enrollment target is 88 participants.
The verdict
NCT02144181, a NA study, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
This is a prospective, multi-site (up to 5 sites), single-blinded, randomized trial. Up to 88 subjects will be enrolled and randomized to one of four treatment groups (4 Groups of 22 subjects), and will receive study treatments based on their assigned treatment group. Following study treatments, follow-up visits will occur at 90, 180 and 365 days from each subject's last study treatment.
Interventions
- DEVICE Ulthera System Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02144181
The ClinicalTrials.gov registry entry for NCT02144181 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ulthera, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ulthera System Treatment is the first listed.
NCT02144181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02144181 about?
NCT02144181 is a clinical study titled "Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea". This is a prospective, multi-site (up to 5 sites), single-blinded, randomized trial. Up to 88 subjects will be enrolled and randomized to one of four treatment groups (4 Groups of 22 subjects), and will receive study treatments based on their assigned treatment group. Following study treatments, fol...
What is the current status of trial NCT02144181?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2014-05. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02144181?
The interventions under investigation include: Ulthera System Treatment (DEVICE).
Who is sponsoring clinical trial NCT02144181?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.